• 出版社/出版日：Mordor Intelligence / 2018年5月21日
|Single User（1名様用）||￥459,000 (USD4,250)||▷ お問い合わせ|
|Team User（7名様用）||￥486,000 (USD4,500)||▷ お問い合わせ|
|Corporate User||￥945,000 (USD8,750)||▷ お問い合わせ|
The global smoking cessation and nicotine de-addiction products market is expected to register a CAGR of about 14% during the forecast period, 2018-2023. Smoking is one of the major causes of lung cancer and other respiratory and cardiac diseases. Awareness about these health hazards has influenced individuals to adopt smoking cessation therapy. Awareness digital media, print media, and other sources of information have proved to be effective in curbing the nicotine addiction crisis to some extent.
Lifestyle Related Issues Leading to Stress
Tobacco use is risky behavior among youth that extends into adulthood. Quitting smoking is beneficial to health at any age, and smokers who quit before 35 years of age have mortality rates similar to those who never smoked. Of the current 44.5 million smokers in the United States, 70% (31 M) claim they would like to quit, 70% of smokers visit a physician yearly, and 46% report an attempt to quit smoking in the past year, which leads to high usage of De-addiction products. Also, this portrays the rising awareness of the population and their willingness to quit smoking. The rise in awareness is also fueled by government efforts, such as advertisements, and distribution of educational pamphlets, etc. Also, there are non-government organizations working to educate and help people quit smoking are that are engaged dedicatedly to bring the number of smokers down. This will allow the smoking cessation and nicotine de-addiction products market to flourish during the forecast period. Other factors that will help the market to grow during the forecast period include introduction of new products and reimbursement for smoking cessation therapy.
Lifestyle Related Stress Triggering Smoking
Most adults say that they smoke because of habit or routine and/or because it helps them relax and cope with stress. Many smokers are more likely to increase their cigarette use when they’re under pressure. Certain events, such as holidays, job changes, and life transitions, can trigger certain habits, including smoking. The idea that people smoke cigarettes to help ease the signs and symptoms of stress is known as ‘self-medication’. Stress is very common, affecting us when we feel unable to cope with unwelcome pressure. It can cause physical symptoms, like headaches or breathlessness, as well as making people feel irritable, anxious or low. Owing to this more people are reluctant to quit smoking and with the addition of new smokers every day the growth of the smoking cessation and nicotine de-addiction products market will have a negative impact during the forecast period. Other factors that will act as restraints for the market include low awareness about smoking cessation products in developing economies and legal obligations dragging growth of several smoking cessation product segments.
Asia-Pacific to Show Fastest Growth
North America is expected to dominate the market during the forecast years, due to increasing number of smokers and growing awareness regarding health hazards associated with smoking. Asia-Pacific is expected to be the fastest growing region for the market, due to increasing awareness about the smoking cessation and nicotine de-addiction products and a huge population base in the area.
Key Developments in the Market:
• December 2017 – US Food and Drug Administration announced an adult smoking cessation education campaign aimed at encouraging cigarette smokers to quit through messages of support that underscore the health benefits of quitting. These messages will be displayed in and around gas stations and convenience stores – retail locations where smokers face a multitude of triggers and that typically feature cigarette advertisements
Major Players: CIPLA LTD., GLAXOSMITHKLINE PLC, IMPERIAL TOBACCO COMPANY OF INDIA LIMITED., MCNEIL AB, NJOY, INC., NOVARTIS INTERNATIONAL AG, PFIZER, INC., REVOLYMER PLC AND TAKEDA PHARMACEUTICAL CO., LTD., amongst others.
Reasons to Purchase the Report
• Current and future smoking cessation and de-addiction products market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needsレポート目次
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Awareness About Smoking Health Hazards And Smoking Cessation Therapy
6.1.2 Introduction Of New Products
6.1.3 Reimbursement For Smoking Cessation Therapy
6.2 Market Restraints
6.2.1 Low Awareness About Smoking Cessation Products In Developing Economies
6.2.2 Lifestyle Related Stress Triggering Smoking
6.2.3 Legal Obligations Dragging Growth Of Several Smoking Cessation Product Segments
6.4 Key Challenges
7. Market Segmentation
7.1 By Type
7.1.1 By Nicotine Replacement Therapies
188.8.131.52 Nicotine Gums
184.108.40.206 Nicotine Patches
220.127.116.11 Nicotine Sprays
18.104.22.168 Nicotine Inhalers
22.214.171.124 Nicotine Lozenges
126.96.36.199 Nicotine Sub lingual Tablets
7.1.2 Smoking Cessation and Nicotine De-addiction Products
188.8.131.52 Bupropione (Zyban)
184.108.40.206 Global Varenicline (Champix, Chantix)
7.2 By Geography
7.2.1 North America
220.127.116.11 United States
18.104.22.168 United kingdom
22.214.171.124 Rest of Europe
126.96.36.199 Australia & New Zealand
188.8.131.52 South korea
184.108.40.206 Rest of Asia-Pacific
7.2.4 Rest of World
220.127.116.11 Saudi Arabia
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Cipla Ltd.
9.2 GlaxoSmithKline plc
9.3 Imperial Tobacco Company of India Limited.
9.4 McNeil AB
9.5 NJOY, Inc.
9.6 Novartis International AG
9.7 Pfizer, Inc.
9.8 Revolymer PLC
9.9 Takeda Pharmaceutical Co., Ltd.
9.10 List Not Exhaustive
10. Future of the Market